Christi Shaw, Kite CEO (Jeff Rumans)
Gilead and Kite nab another approval for Tecartus, as leading CAR-T portfolio continues to grow
Gilead and Kite took another step Friday toward expanding their franchise of CAR-T drugs, nabbing a new approval for Tecartus.
The FDA OK’ed the therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
